TD Cowen initiated coverage of Vor Bio (VOR) with a Buy rating and no price target The firm cites telitacicept’s “promising” mechanism of action, “differentiated strong data,” and potential across several indications for the Buy rating.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio prices 13.88M shares at $10.81 in private placement
- Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs
- Vor Biopharma Approves Stock Option Repricing Plan
- Vor Bio initiated with an Overweight at JPMorgan
- Vor Bio assumed with a Neutral at Wedbush